Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Although often requiring the development of efficient adjuvants, needle-free mucosal delivery of vaccine is of major interest as a strategy of mass immunization against infectious diseases. We report that mucosal immunization against tetanus toxoid through nasal route, together with active cytotoxic necrotizing factor 1 (CNF1), elicits a specific and long lasting anti-tetanus toxin response, comprising seric IgG and IgA, as well as mucosal IgA. Immunized mice were protected against a challenge with lethal doses of tetanus toxin (10 x LD(50)). The Rho GTPase activating toxin CNF1 is thus an attractive mucosal adjuvant candidate for nasal vaccines.
Institut National de la Santé et de la Recherche Médicale, INSERM, U627, Université de Nice-Sophia Antipolis, Faculté de Médecine, 28 Avenue de Valombrose, F-06107 Nice cedex 2, France. munro@unice.fr
Patrick
P
Munro
Gilles
G
Flatau
Emmanuel
E
Lemichez
D000276:Adjuvants, Immunologic; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000097:blood; D001427:Bacterial Toxins / Q000276:immunology*; D029968:Escherichia coli Proteins / Q000276:immunology*; D005243:Feces / Q000737:chemistry; D005260:Female; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000276:immunology; D017817:Nasal Lavage Fluid / Q000737:chemistry; D016019:Survival Analysis; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control*; D013745:Tetanus Toxoid / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D029968:Escherichia coli Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D013745:Tetanus Toxoid; C060296:cytotoxic necrotizing factor type 1